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It has been reported that monocytes, Langerhans cells (LC) and other dendritic cells (DC) express the high-afﬁnity
receptor for IgE (FceRI) in patients with atopic diseases. These cells may be instrumental in the control of the
immune response and the allergic inﬂammation. In this context, transforming growth factor beta 1 (TGF-b1) has
been highlighted as a key cytokine involved in the mechanisms aimed to orchestrate tolerance and has been
suggested as a candidate gene in atopic diseases. In this report, we investigate the putative role of TGF-b1 in the
regulation of FceRI on cord blood CD34þ stem cell-derived CD1aþ DC (CD34-derived CD1aþ DC). Kinetic exper-
iments show that FceRI spontaneously appears on the surface of CD1aþ DC, but decreases when exogenous TGF-
b1 is added at high doses (10 ng per mL) or when endogenous TGF-b1 is neutralized in the culture conditions. In
contrast, low-dose TGF-b1 (0.5 ng per mL) stabilizes surface FceRI expression on DC. Increasing TGF-b1 concen-
trations leads to the generation of LC-like DC showing an augmentation in stimulatory capacity towards allogeneic
T cells. In view of these data, a picture emerges that FceRIþ on DC is ﬁnely modiﬁed by the TGF-b1 concentration in
the microenvironment and could be of primary relevance in the context of atopic diseases.
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The identification of the high-affinity receptor for IgE (FceRI)
on the surface of professional antigen-presenting cells
(APC) from the myeloid lineage such as monocytes (Mo)
and dendritic cells (DC) in the blood or tissue of atopic in-
dividuals lead to a new view of cellular distribution and
functionality of this structure (Bieber, 1997). Interestingly, in
contrast to basophils and mast cells, FceRI surface expres-
sion on Mo and DC is highly variable. Therefore, factors
regulating the FceRI surface expression are of primary in-
terest since they are crucial for our understanding of the
physiological and pathophysiological role of this structure.
In the last decade, much progress has been made in the
development of in vitro models for the generation of large
numbers of DC. The first strategy is based on the gener-
ation of so-called Mo-derived DC. Alternatively, DC can be
derived from CD34þ stem cells obtained from human adult
or cord blood. Detailed analysis revealed that under appro-
piate conditions, CD34þ -derived cells have the capacity to
acquire distinct properties of DC subtypes (Caux et al, 1992;
Banchereau and Steinman, 1998). In previous studies, a
varying spontaneous surface expression of FceRI on in vitro
generated CD1aþ DC has been reported (Geiger et al,
2000). For Mo-derived CD1aþ DC it has been shown re-
cently that intracellular a-chain (FceRIa) accumulates during
DC differentiation, whereas the expression of g-chains
(FceRIg) mandatory for surface expression, is downregulat-
ed. It is low or negative in DC from normal donors lacking
surface FceRI (FceRI DC). In contrast, CD1aþ DC from
atopics show significant FceRIg expression and display
surface FceRI (FceRIþ DC) (Novak et al, 2003).
Recently, it has been demonstrated that transforming
growth factor-b1 (TGF-b1) contributes to the generation of
FceRI bearing DC from circulating monocytes (Reich et al,
2001). TGF-b1 is a multifunctional growth factor belonging
to a superfamily of regulatory proteins and it has been sug-
gested that variations of TGF-b in the peripheral blood and
affected tissues influence the development and course of
atopic diseases (Lee et al, 2000; Arkwright et al, 2001).
Furthermore, genetic studies aiming to detect atopy-related
single nucleotide polymorphisms of the TGF-b1 gene have
suggested this cytokine as a putative candidate gene for
atopic conditions since they could encode for low-producer
individuals (Arkwright et al, 2001; Pulleyn et al, 2001). These
observations prompted us to investigate the putative role of
TGF-b1 in the regulation of FceRI on CD34-derived CD1aþ
DC generated in vitro from CD34þ stem cells and we eval-
uated their functional characteristics.
Abbreviations: 7AAD, 7-aminoactinomycin-D; APC, antigen-pre-
senting cells; DC, dendritic cells; FCS, fetal calf serum; FceRI,
high-affinity IgE receptor; FceRIa, alpha-chain of the high-affinity
IgE receptor; FceRIg, gamma-chain of the high-affinity IgE recep-
tor; LC, Langerhans cells; MHC I, major histocompatibiliy complex
I; MHC II, major histocompatibility complex II; PE, phycoerythrin;
TGF-b1, transforming growth factor beta 1
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Results
TGF-b regulates the generation of CD34-derived CD1aþ
DC during in vitro In a first attempt, we evaluated the ef-
fect of different concentrations of TGF-b1 on CD34þ stem
cell cultures. By this, we could show that addition of TGF-b1
both at low (TGF-b1low) and high (TGF-b1high) concentra-
tions significantly increased the generation of CD34-derived
CD1aþ DC compared to control cultures (CON) without any
TGF-b1 supplementation (CON: 23.90%  SEM 2.02, TGF-
b1low: 56.24%  SEM (2.81 and TGF-b1high: 63.4%  SEM
3.85). It has been shown previously that a high TGF-b1 level
sustains hematopoetic immaturity, whereas neutralization of
endogenous and autocrine TGF-b1 sustains undifferentiat-
ed cells (Ottmann and Pelus, 1988; Fortunel et al, 2000).
Moreover, culture condition under TGF-b1high did not only
decelerate cell proliferation as indicated by lower total cell
number in our system (Fig 1A) but also decelerated the dif-
ferentiation of CD34þ stem cells. In contrast to CD34-
derived CD1aþ DC generated under control conditions,
CD34þ stem cells were still detectable in cultures with TGF-
b1low and TGF-b1high after 9 d (Fig 1B). From these first
series of experiments, we conclude that increasing amounts
of TGF-b1 enhance the generation of CD34-derived CD1aþ
DC but decelerate cell proliferation and sustain cell imma-
turity.
IgE and low concentrations of TGF-b1 stabilize FceRI on
in vitro generated CD1aþ DC To investigate the regulation
of the FceRI expression of CD34-derived CD1aþ DC during
their in vitro differentiation, cells were subjected to detailed
flow cytometric analyses. FceRI appeared on the cell sur-
face of CD34-derived CD1aþ DC under all three investi-
gated conditions and peaked around day 5. The receptor
expression stabilized at high level under control condition
and TGF-b1low. In contrast, FceRI was rapidly downregu-
lated on CD34-derived CD1aþ DC generated with TGF-
b1high and on day 9 only few cells bearing FceRI could be
detected (Fig 2A). In order to create an atopy-like micro-
enviroment, CD34-derived CD1aþ DC were generated in
the presence of IgE since it has been shown that its binding
to FceRIa may contribute to the upregulation of the receptor
on APC (Reischl et al, 1996; Borkowski et al, 2001). These
culture conditions lead to a further significant increase of
the FceRI expression of CD34-derived CD1aþ DC (Fig 2B).
Thus, FceRI is constitutively expressed on the surface of
CD34-derived CD1aþ DC during their cell differentiation
from CD34þ stem cells, but this expression is subjected to
further regulatory effects depending on the presence of
TGF-b1 and IgE in the microenvironment.
TGF-b1 regulates the expression of FceRI subunits FceRI
on APC differs from the tetrameric FceRI found on the ef-
fector cells of anaphylactic reactions by lacking the b-chain
and consisting only of an IgE-binding a-chain and two di-
sulfide linked g-chain (Turner and Kinet, 1999). In addition, a
high amount of FceRIg, preferently found on APC of atopic
individuals, is mandatory for the FceRI surface expression
(Maurer et al, 1994; Maurer et al, 1996). Thus, to arrive at the
exact structure of FceRI on CD34-derived CD1aþ DC and
the protein level of the respective FceRIa and FceRIg chains
on CD34-derived CD1aþ DC, we performed extracellular
and intracellular flow cytometric analyses in combination to
semiquantitative PCR experiments. The latter showed com-
parable amounts of FceRIa and FceRIg transcripts under all
three cell culture conditions used (Fig 3A), whereas FceRI b-
chain remained undetectable (data not shown). Importantly,
Figure 1
TGF-b1 decelerates cell proliferation and sustains cell immaturity.
(A) The highest cell yield was detected in control culture (CON). TGF-
b1low and TGF-b1high decreased total cell proliferation with the lowest
cell yield under high TGF-b1high (n¼26). (B) In contrast to control cul-
ture (CON), CD34pos stem cells were still detectable on day 9 in cultures
with TGF-b1low and TGF-b1high (n¼11).
Figure2
FceRI expression of CD34-derived CD1aþ DC during differentia-
tion and on day 9. (A) FceRI regularly appears on differentiating CD34-
derived CD1aþ DC under all conditions peaking around day 5 and
stabilizing under control condition (CON) and TGF-b1low (n¼ 7). (B)
Addition of IgE resulted in an increased FceRI expression of CD34-
derived CD1aþ DC under all culture conditions. On day 9, FceRI could
even be demonstrated on CD34-derived CD1aþ DC generated with
TGF-b1high (n¼5). Mean values  SEM of five experiments are shown
in the upper right corner of the histogram including p values.
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transcripts of tryptase as a control for contaminating mast
cells or basophils could not be detected (data not shown).
Since CD34-derived CD1aþ DC were generated in FCS,
which served as a source of TGF-b1, we determined the
level of endogenous TGF-b1 in the cell culture supernatant
of control condition on day 9. As expected, an average of
0.03 ng per mL (SEM  0.01, n¼ 6) TGF-b1 could be de-
tected. This corresponds to the amount of TGF-b1 from
FCS supplementation of culture medium and excludes and
TGF-b1 producing source such as platelets in our cell cul-
ture system. Complete neutralization of endogenous TGF-b
leads to rapid downregulation of the FceRI surface expres-
sion on day 9. Interestingly, both receptor subunits, intra-
cellular FceRIa and FceRIg were hardly detectable and only
trackable in decreased amounts after TGF-b neutralization
(Fig 3B). Furthermore, control experiments revealed that
supplementation of irrelevant IgG1 antibody did not alter
surface expression of FceRI (data not shown).
CD34-derived CD1aþ DC generated under control con-
ditions displayed a moderate FceRI surface expression,
whereas the highest FceRI surface expression and intra-
cellular FceRI pool of the a-chain was detectable on CD34-
derived CD1aþ DC generated with TGF-b1low (Fig 3C).
Although the intracellular pool of FceRIg was elevated in
CD34-derived CD1aþ DC cultured under control conditions
and TGF-b1low, only low levels of FceRIg were detectable in
CD34-derived CD1aþ DC generated in TGF-b1high (Fig 3C).
Based on these cumulative data, we can conclude that
the presence of TGF-b1 in the microenviroment surrounding
CD34-derived CD1aþ DC is a crucial factor in the control of
surface expression of FceRI on CD34-derived CD1aþ DC.
TGF-b1 concentration as the limiting factor for induction
of FceRI bearing Langherans cells (LC) Several types of
CD34-derived CD1aþ DC have been identified in the
human immune system whereas TGF-b1 is critical for the
generation of LC in vitro (Strobl et al, 1996). Thus we in-
vestigated the amount of the CD1aþ LC subset under
different culture conditions detected by the expression of
Langerin, a lectin receptor specific for LC (Valladeau et al,
2000). Whereas under control conditions, we were not able
to detect LC, these cells could be generated in TGF-b1low.
The highest number of LC among CD34-derived CD1aþ DC
could be detected under TGF-b1high. Interestingly, under
TGF-b1low a remarkable amount of LC were FceRIþ (Fig 4).
Thus, we can conclude that TGF-b1 at defined concen-
trations (TGF-b1low) leads to the generation of FceRIþ LC.
TGF-b derived CD34-derived CD1aþ DC display distinct
phenotypical and functional characteristics To investi-
gate the nature of DC generated under control condition, we
performed morphological and detailed phenotypical analy-
ses in comparison to CD34-derived CD1aþ DC generated
under TGF-b1 supplementation. As reported earlier, addi-
tion of TGF-b1 leads to the formation of clusters (Riedl et al,
2000b) whereas a concomitant increase of E-cadherin—a
homophilic adhesion molecule involved in the cluster for-
mation of LC (Riedl et al, 2000a)—could be observed (Fig
5A). Although we could not find a significant difference in
expression of DC-SIGN/CD209, we could detect on CD34-
derived CD1aþ DC generated under control condition an
increased expression of CD11b and mannose receptor
(CD206) that are not only expressed by macrophages but
also related to DC of non-LC type and are known to be
expressed on so-called inflammatory dendritic epidermal
cells (IDEC) that are usually found in lesional sites of the skin
of atopic eczema patients (Sallusto et al, 1995; Jaksits et al,
1999; Wollenberg et al, 2002) (Fig 5). In addition CD14 could
be detected in approximately equal amounts on CD1a
positive cells under all conditions (Fig 5A). Furthermore the
Figure 3
Alteration of FceRIa and FceRIc in response to different concen-
trations of TGF-b1. (A) Representative results of RT-PCR of highly
enriched CD1aþ cells confirming the presence of FceRIa and FceRIg
(1¼ control condition, 2¼TGF-b1low, 3¼TGF-b1high, n¼ 3) (B) Block-
ing endogenous TGF–b with an monoclonal anti-TGF-b antibody in
control condition culture leads to a decreased surface FceRI expression
on CD34-derived CD1aþ DC on day 9 accompanied by a strong de-
crease of intracellular FceRIa and FceRIg (n¼ 7) Furthermore, control
experiments revealed that supplementation of irrelevant IgG1 antibody
did not alter surface expression of FceRI (data not shown). (C) In con-
trast to CD34-derived CD1aþ DC generated under control culture
(CON) and TGF-b1low, TGF-b1high downregulated FceRI surface ex-
pression on CD34-derived CD1aþ DC by decreasing the intracellular
pool of FceRIg. Intracellular FceRIa was present under all conditions
with the strongest detection in CD34-derived CD1aþ DC generated
with TGF-b1low. Representative histograms of 12 experiments are
shown.
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addition of exogenous TGF-b1 augmented the expression
of major histocompatibility complex (MHC) class I and II
complexes and costimulatory molecules, but did not result
in the final maturation of CD34-derived CD1aþ DC indicat-
ed by lack of CD83, a marker for mature DC (Fig 5B) (Zhou
and Tedder, 1996).
To investigate the influence of TGF-b1 on the functional
properties of FceRIþCD34-derived CD1aþ DC, we tested
their stimulatory activity in an allogeneic system. As shown
in Fig 6, the addition of TGF-b1 leads to generation of
CD34-derived CD1aþ DC, which display a significant in-
creased allogeneic stimulatory activity.
Discussion
TGF-b1 is a pleiotropic regulator of the hematopoesis,
which displays a growth inhibitory effect on early progenitor
cells and influences distinctly the differentiation of CD34-
derived CD1aþ DC (Fortunel et al, 2000).
In this study, we investigated the involvement of TGF-b1
in the regulation of the FceRI a- and g-chains and the
differentiation of FceRI bearing subsets of CD34-derived
CD1aþ DC. We uncovered that especially the intracellular
FceRIg pool, which is mandatory for sufficient FceRI surface
expression, is distinctly adjusted by the amount of TGF-b1,
whereas the regulation of FceRIg subunits occur at the
protein but not at the mRNA level suggesting that TGF-b is
involved in the regulation of the g-chain at a post-transcrip-
tional point. Another group reported similar findings of g-
chain regulation in Mo-derived macrophage where infection
of the cells with HIV lead to downregulation of g-chain
on protein level but did not alter the mRNA expression
(Kedzierska et al, 2002). Just recently, another group re-
ported that TGF-b1 suppressed expression of Fcg–recep-
tors on human myeloid cells by downregulating the g-chain,
which is identical to FceRIg (Ra et al, 1989; Tridandapani
et al, 2003).
At early differentiation stages, FceRI is constitutively ex-
pressed on the cell surface of the differentiating CD34-
derived CD1aþ DC. Later on, low or moderate TGF-b1
levels facilitate the differentiation of FceRI bearing CD34-
derived CD1aþ DC subtypes such as Langerinþ LC and
Langerin CD34-derived CD1aþ DC. In contrast, the addi-
tion of TGF-b1 at high doses and the total elimination of
TGF-b from the surrounding micromilieu prevent the gen-
eration of FceRIþ CD34-derived CD1aþ DC subtypes dur-
ing further differentiation and accelerate the differentiation
of FceRI CD34-derived CD1aþ DC such as LC and La-
ngerin CD34-derived CD1aþ DC. TGF-b1 seems to play a
major role in the regulation of FceRI since the generation of
the different FceRIþ DC subtypes in combination with a
distinct intracellular FceRIa and FceRIg pool were influenced
by addition of exogenous TGF-b1. As we used a TGF-b
blocking antibody which was directed against TGF-b1, b2,
and b3, we cannot exclude that downregulation of FceRI
results from an cooperative effect of all TGF-b isoforms.
Even though increasing evidence arises that TGF-b1
plays a pivotal role in atopic diseases, its influence on the
expression of the high-affinity receptor for IgE on human
APC has not been investigated in detail before. In the past,
studies have shown that atopic diseases such as atopic
Figure 4
High amounts of FceRIþ LC were generated with TGF-
b1low. The generation of CD34-derived CD1aþ DC and LC
depended on exogenous TGF-b1 supplementation. The
highest amounts of Langerinþ LC were generated under
TGF-b1high followed by LC generated with TGF-b1low. Un-
der control culture (CON) virtually no Langerinþ LC could
be detected. A high percentage among the LC population
expressed FceRI especially in cultures with TGF-b1low
(n¼ 5).
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dermatitis go along with a low TGF-b1 producing phenotype
(Lee et al, 2000; Arkwright et al, 2001). These findings are
largely compatible with recent data, which predict that in
some instances defects in the TGF-b1 production contrib-
ute to human diseases such as allergic hypersensitivity dis-
orders (Sugai et al, 2003). These are characterized by an
excessive IgE serum level in combination with an enhanced
FceRI surface expression on DC in the peripheral blood and
tissues. Further on, it has been shown that TGF-b is largely
involved in the regulation of the IgE synthesis itself and
displays a downregulatory function on IgE serum levels
(Wu et al, 1992; Sugai et al, 2003). In healthy, non-atopic
individuals, high TGF-b serum levels prevail. The epidermal
skin lesions of atopic dermatitis are characterized by high
numbers of FceRI-bearing LC and another FceRI bearing
DC subtype, the so-called IDEC. In contrast in the skin of
healthy, non-atopic individuals IDEC are completely absent
and FceRI LC attend in the epidermis (Wollenberg et al,
1995). In view of the data presented here, low or moderate
TGF-b1 producing phenotype which are a pathognomonic
feature of atopic individuals could promote the develop-
ment of FceRIþ DC subtypes in vivo. Since FceRI appears
on the cell surface of CD34-derived CD1aþ DC during
differentiation, IgE as a receptor stabilizing mechanism via
FceRIa binding (Borkowski et al, 2001) might further con-
tribute to the high FceRI expression on DC in atopic indi-
viduals, whereas in an non-atopic enviroment regular TGF-b
levels could inhibit FceRI surface expression on DC.
Together, these components might trigger the generation
of the pathophysiologically relevant FceRIþ DC subtypes,
which might perpetuate the course of pro-inflammatory and
allergic processes of atopic diseases by their high antigen-
presenting and stimulatory capacities in vivo.
Whether the wide margin of fluctuation of active TGF-b1
levels in the human cord blood might bias or prevent se-
lectively the development of these potent players in the
atopic game in vivo and, therefore, serve as a predictive
factor for the generation of atopic diseases later in life,
remains to be elucidated.
Material and Methods
Reagents Phycoerythrin (PE)-labeled T6RD1 (IgG1, Beckman
Coulter, Krefeld, Germany), unlabeled IOT6a (IgG1, Beckman
Coulter) and Cy-Chrome-labeled HI149 (IgG1, Beckton Dickinson
(BD), Heidelberg, Germany) recognize CD1a. FceRI was detected
by mAb 22E7 (IgG1) directed against the a-chain not interfering
with the IgE binding site; mAb 4D8 (IgG2b) is directed against the
g-chain. These antibodies were prepared and characterized as
described elsewhere (Riske et al, 1991; Schoneich et al, 1992);
mAb IOT2b (IgG1) directed against HLA-DR, mAb M5E2 (IgG2a)
directed against CD14, mAb BEAR-1 (IgG1) detecting CD11b and
mAb HB15a detecting CD83 (IgG2b) were purchased from (Immuno-
tech, Marseille, France). MAb DCN46 (IgG2b) against DC-SIGN/
CD209, mAb 19 (IgG1) detecting CD206 and mAb B70/B7-2 (IgG1)
directed against CD86 and mAb 5C3 (IgG1) directed against CD40
(IgG1) were from BD. Mab. BB-1/B7 (IgG1) reacting with CD80 and
PE-labeled 8G12 (IgG1) directed against CD34 were from BD, pu-
rified and PE-labeled mAb DCGM4 (IgG1) recognizes LC-specific
Birbeck Granules (BG)-associated lectin Langerin/CD207 (Immuno-
tech). MAb 67A4 (IgG1) detecting E-cadherin was purchased from
Beckman-Coulter. MOPC-21 (IgG1, Sigma, Deisenhofen, Germa-
ny), mAb 1D11 is directed against TGF-b1, -b2, -b3 (IgG1, R&D
Systems, Minneapolis, Minnesota). MOPC-21 (IgG1), UPC10
(IgG2a), MOPC-141 (IgG2b) all from Sigma and IgG1RD1 (Beck-
Figure 5
Phenotypical and morphological changes induced by TGF-b1. (A)
Representative histograms of E-cadherin, Langerin, CD11b, CD14,
CD206 and DC-SIGN on CD34-derived CD1aþ DC (n¼ 5). (B) Repre-
sentative phase contrast microscopic images of cells cultured with
control condition, TGF-b1low and TGF-b1high and representative histo-
grams co-stimulatory molecules and MHC class I and II complex,
which were up-regulated through addition of exogenous TGF-b1 (TGF-
b1low, TGF-b1high). Note the enhanced cluster formation in cultures
supplemented with exogenous TGF-b.
Figure6
TGF-b leads to enhanced allogeneic stimulatory capacity of
CD34-derived CD1aþ DC. DC were co-cultured with autologous or
allogeneic T cells for 5 d as described in Material and Methods. CD34-
derived CD1aþ DC generated in the presence of exogenous TGF-b1
(TGF-b1low, TGF-b1high) lead to an increased stimulatory capacity
towards allogeneic T cells (n¼ 5).
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man-Coulter) were used as appropriate isotype controls. Fluo-
rescein-isothiocyanate (FITC)-conjugated goat anti-mouse (GaM/
FITC) antibody was from Jackson Laboratories (West Grove,
Pennsylvania). Sheep anti-mouse coated magnetic beads
(M-280) were obtained from Dynal (Oslo, Norway). Normal mouse
serum for blocking purposes, 7-aminoactinomycin-D (7AAD) and
2-mercaptoethanol were from Sigma. Human myeloma IgE (PS)
was obtained from Calbiochem (Bad Soden, Germany). Heat-
inactivated fetal calf serum (FCS), antibiotics/antimycotics and
RPMI-1640 with Glutamax were all from Invitrogen (Carlsbad, Cal-
ifornia). Granulocyte macrophage colony stimulating factor (GM-
CSF) was purchased from Novartis Pharma (Nu¨rnberg, Germany),
tumor necrosis factor (TNF-b, stem cell factor (SCF), Flt-3-ligand
(FL3) and TGF-b1 were purchased from R&D Systems.
Puriﬁcation of CD34þ stem cells Cord blood was obtained from
vaginal or cesarean deliveries after informed written consent from
patients according to local Medical Ethics Committee of the Uni-
versity of Bonn, Germany and the study was performed according
to Declaration of Helsinki Guidelines. After the blood was diluted
three times with RPMI-1640 (Invitrogen), 25 mL of suspended cells
was overlayed on 15 mL of Lymphoprep (Nycomed, Oslo, Norway).
peripheral blood mononuclear cells (PBMC) were isolated as in-
terface cells after density gradient centrifugation (20 min at
900  g at room temperature). To reduce residual platelets, the
recovered cells were washed twice in PBS and recovered in PBS
supplemented with 1% BSA and 5 mmol EDTA. Isolation of CD34þ
cells was performed using magnetic microbeads coupled to anti-
CD34 antibody and the AUTOMACS system (Milteny Biotec, Be-
rgisch Gladbach, Germany) according to the manufacturer’s pro-
tocol. The enrichment of CD34þ cells was determined with an PE-
conjugated anti-CD34 mAb and was more than 90% CD34þ cells.
Culture of CD34þ stem cells 4  104 purified CD34þ cells were
cultured in 24-well plates (Corning, Acton, Massachusetts) with 0.5
mL RPMI-1640 with Glutamax (Invitrogen) supplemented with 10%
heat inactivated FCS (Invitrogen), 1% antibiotics/antimycotics
(Invitrogen) and 5 mM ME (Sigma). Since it has been shown that
combination of GM-CSF, TNF-a, SCF, FL3, and TGF-b1 give rise to
a great number of CD34-derived CD1aþ DC (Strobl et al, 1997), we
used GM-CSF (300 IU per mL), TNF-b (50 IU per mL), SCF (10 ng
per mL), and FL3 (10 ng per mL) in FCS supplemented medium as
control culture conditions. We performed ELISA to analyze the
amount of TGF-b1 in the FCS charges used for medium supple-
mentation. We detected an average TGF-b1 concentration of 0.39
ng per mL (SEM  0.09; n¼ 3). Since we used 10% FCS supple-
mented medium we expected an endogenous TGF-b1 concentra-
tion of 0.04 ng per mL. Hereafter, the baseline condition will be
referred to as control. According to TGF-b1 levels found in cord
blood (0.89 ng per mL, SEM  0.08, n¼ 16) and to a previous
study (Strobl et al, 1996), we defined low and high exogenous TGF-
b1 culture conditions as follows: low TGF-b1 (TGF-b1low) with 0.5
ng per mL and high TGF-b1 (TGF-b1high) with 10 ng per mL which
were added to control conditions. The cells obtained will be refered
to as CD34-derived CD1aþ DC.
Generation and culture of CD34-derived CD1aþ DC were
maintained for 9 d for kinetic experiments. One-half of the medium
was replaced with fresh cytokines after 4 and 8 d. To mimic an
atopic environment CD34þ cells were cultured as described above
in addition to 1 mg per mL human myeloma IgE (every other days).
Photographs were taken with a DMCRB microscope (Leica, Bens-
heim, Germany) using an HV-C2OA digital camera (Hitachi, Dues-
seldorf, Germany) and Diskus software (Hilgers, Koenigswinter,
Germany).
Enrichment of CD1aþ DC For RNA extraction, CD1aþ DC were
enriched from the culture conditions using an anti-CD1a mAb
bound to magnetic beads according to the manufacturer’s proto-
col. Briefly, Dynabeads M-280 precoated with sheep anti-mouse
mAb were incubated with anti-CD1a mAb IOT6. After washing
procedures, DC cell suspensions were added to the bead sus-
pensions and incubated for 1 h at 41C. CD1aþ cells bound to the
beads were then purified by four rounds of washing procedures
with the magnet, yielding purity greater than 98% as controlled by
light microscopy.
Flow cytometric analysis and ELISA Double-staining experi-
ments with saponin or digitonin for the detection of surface or
intracellular distribution of FceRI subunits were performed as de-
scribed in detail (Kraft et al, 1998). For triple-staining experiments
cells were incubated with Cy-chrome-labeled CD1a and PE-labe-
led Langerin after permeabilization. Saponin permeabilization was
used for detection of intracellular FceRIa, whereas digitonin perm-
eabilization was used for detection of FceRIg expression. Cells
were acquired using a FACSCalibur flow cytometer (BD) as de-
scribed in detail elsewhere (Novak et al, 2001). For quantitative
evaluation, the CD1aþ population was gated manually and the
percentage of FceRIaþ or FceRIgþ cells was determined using
Lysis II software (BD).
Immunolabeling for phenotyping was performed as reported
(Wollenberg et al, 1999). As a control, cells were stained with cor-
responding isotype-matched control immunoglobulin. All incubat-
ions and washes were performed at 41C. Results are expressed as
percent of positive cells.
TGF-b1 levels in cord blood plasma and culture supernatants
were determined by ELISA according to the manufacturer’s pro-
tocol (Quantikine, R&D Systems) and as described in detail (Novak
et al, 2001).
Ampliﬁcation of mRNA and analysis of transcripts Total RNA
was extracted after 9 d of culture from highly purified CD34-de-
rived CD1aþ DC using Trizol (Life Technologies, Eggenstein, Ger-
many) following the manufacturer’s instructions. RT reactions were
performed using 1 mg of total RNA. Denaturation at 941C for 40 s
was followed by annealing of the primers at 551C for 30s and
extension at 721C for 30s. A final extension phase of 5 min was
added. Specific primer sequences for each gene were as follows:
human b-actin: sense, 50-GAG CGG GAA ATC GTG CGT GAC ATT-
30; antisense, 50-GAT GGA GTT GAA GGT AGT TTC GTG-30, yield-
ing a fragment of 240 bp; human FceRIg: sense, 50-CTG TTC TTC
GCT CCA GAT GGC GT -30; antisense, 50-TAC AGT AAT GTT GAG
GGG CTC AG -30 (fragment of 536 bp), human FceRIgsense, 50-
CCA GCA GTG GTC TTG CTC TTA C-30 and antisense: 50-GCA
TGC AGG CAT ATG TGA TGC C-30 (fragment of 338bp), human
FceRIb sense, 50-GGA CAC AGA AAG TAA TAG GAG AG and an-
tisense: 50-GAT CAG GAT GGT AAT TCC CGT T (fragment of 446
bp) and human tryptase sense, 50-CTC CCT CAT CCA CCC CCA
GT and antisense: 50-GGA TCC AGT CCA AGT AGT AG (fragment
of 616 bp). Amplification was performed on a Perkin-Elmer Gene
Amp PCR System 9600 thermocycler (Applied Biosystems,
Weiterstadt, FRG). The PCR cycle numbers for the amplification
of the respective cDNAs were 25 for b-actin and 30 for FceRIa and
FceRIg. Specific PCR fragments were separated on a 1% agarose
gel and visualized using ethidium bromide staining. The PCR
products were evaluated semiquantitatively by comparing the ratio
of the specific products versus the b-actin band by digital image
analysis using the WinCam system (Cybertech, Berlin, Germany).
T cell proliferation assays Proliferation assays were performed in
a total volume of 200 mL in 96-well round-bottom plastic culture
plates using allogeneic T cells as responder cells. Allogeneic T cells
were isolated from PBMC of healthy volunteers using a nylon-wool
column (485% purity as assessed by anti-CD3 staining). DC were
cultured as described above until day 9 of culture. In allogeneic
assays, triplicates of DC containing 100, 200, or 1000 viable
CD1aþ DC/well were incubated with 100,000 viable allogeneic T
cells at 371C for 3 d. Proliferative response was then measured by
addition of 1 mCi 3H-thymidine incorporation for 12 h. The incor-
porated radioactivity was measured in a liquid scintillation counter
(1450 MicroBeta Trilux, Wallac). Relative stimulation indices (rSI)
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were calculated as follows: rSI¼ (c.p.m. (DCþT cells)c.p.m.
(T cells)/cpm (T cells).
Statistical analysis For statistical evaluation of significances, the
Wilcoxon test was performed. Correlations were calculated by
Pearson’s linear regression analysis. These tests were realized us-
ing the SPSS 10.0 software (SPSS, Chicago, lllinois). Results are
shown as arithmetic mean  standard error of the mean (SEM)., po0.05, , po0.01, n.s., not significant.
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